Talk:Cancer vaccine

message: I don't get this: 
:Do not randomize antigen plus adjuvant versus adjuvant alone. The goal is to establish clinical benefit of the immunotherapy (i.e.,adjuvanted vaccine) over the standard of care, not over standard of care plus adjuvant. The adjuvant may have a low-level clinical effect that would skew the statistical powering of the trial, increasing the chances of a false negative.
Suppose the adjuvant has a clinical effect, but the vaccine is ineffective. You'd get improvement in the treatment group, and attribute it to the vaccine, even though the vaccine is ineffective. Right? Nbauman (talk) 17:54, 23 January 2009 (UTC)
replies: text: Almost. I read it as the 'adjuvant alone' group is the control (presumably to allow blinding) rather than part of the treatment group. Hence if the adjuvant by itself has a benefit then the vaccine will have to have a stronger benefit to 'pass' the trial. Rod57 (talk) 07:28, 12 August 2009 (UTC)

text: Yes, let's just delete this Recommendations section. It does not seem relevant/specific enough or worth reading. - Rod57 (talk) 14:01, 10 July 2016 (UTC)
thread_title: Drug Development

message: Could restructure/split to show which are autologous therapeutic cancer vaccines and which are not. Rod57 (talk) 22:31, 18 October 2010 (UTC)
thread_title:  Restructure 

message: I recently fixed a link (used to go to different types of cancer; now goes to Types of cancer) in the main section, but it seems sort-of out of place to me. Types of cancer are, of course, important in an article about a cancer vaccine, but should the link not have some sort of introduction/explanation? BobFijiwinkle (talk) 22:13, 3 April 2011 (UTC)
thread_title:  Types of cancer link 

message: A New Ally against Cancer; The FDA recently okayed the first therapeutic cancer vaccine, and other drugs that enlist the immune system against tumors are under study by Eric von Hofe in September 30, 2011 issue of Scientific American.   97.87.29.188 (talk) 19:07, 27 September 2011 (UTC)
thread_title:  Resource in current [[SciAm]] 

message: Def/overview is slightly confused whether its about cancer prevention or treatment, the rest of the article seems to talk about cancer treatment which seems also to reflect use in publications. Hence I think this article should concentrate solely on cancer treatment and link cancer immunoprevention for prevention. Richiez (talk) 22:02, 1 February 2012 (UTC)
replies: text: I agree. It's still almost totally about therapeutic cancer vaccines and cancer immunotherapies. Perhaps we should rename this page to therapeutic cancer vaccine and give it a hatnote to cancer immunoprevention (cancer vaccine could redirect to this renamed article). Rename ? - Rod57 (talk) 13:55, 10 July 2016 (UTC)
replies: text:  I've tried to add the hatnote (after first line of Intro) - perhaps it should be at the very top ? - Rod57 (talk) 14:35, 10 July 2016 (UTC)
thread_title:  Definition and content mismatch - rename 

message: mostly unsourced or sourced to SPS or primary sources; includes dead things and current things.  tables like this are tempting to create but a nightmare to maintain and generally are OR collections.
;Vaccine candidates
Most of the cancer vaccines in development address specific cancer types and are therapeutic vaccines. These include:
Vaccine candidates
Developer                              	Vaccine                                     	Notes
Aduro                                  	GVAX                                        	formerly developed by Cell Genesys
Advaxis                                	ADXS11-001, ADXS31-001, ADXS31-164          	
                                       	ALVAC-CEA vaccine                           	
Avax Technologies                      	AC Vaccine                                  	
Amgen                                  	talimogene laherparepvec                    	
Biovest International                  	BiovaxID                                    	Phase III
Bavarian Nordic                        	Prostvac                                    	
Celldex Therapeutics                   	CDX110, rindopepimut), CDX1307 and CDX1401  	
The Center of Molecular Immunology,    	CimaVax-EGF                                 	lung cancer
CureVac                                	CV9104                                      	mRNA-based cancer immunotherapy; CV9104 is currently being evaluated in an international Phase 2b trial in patients with castration-resistant prostate cancer.
Dendreon Corp                          	DNDN) Neuvenge                              	HER2/neu expressing cancers such as Breast, Bladder, colon, Ovarian),
Galena Biopharma                       	NeuVax                                      	
Generex Biotechnology (Antigen Express)	Ae-37)                                      	
Geron Corporation                      	GRNVAC1                                     	
GlaxoSmithKline                        	                                            	Melanoma treatment targeting MAGE-A3
GlobeImmune                            	Tarmogens, GI-4000, GI-6207, GI-6301)       	
Heat Biologics                         	ImPACT Therapy                              	NSCLC and other cancers
Immatics biotechnologies               	IMA901                                      	Renal cancer)
Immunitor                              	hepcortespenlisimut-L (Hepko-V5)            	Trials of an oral cancer vaccine A Phase 3 trial in hepatocellular carcinoma was first made public in September 2014.Clinicaltrials.gov https://clinicaltrials.gov/show/NCT02232490
Merck                                  	Stimuvax                                    	in 2009, is starting phase III trials of for breast cancer. It had promising results from a phase IIB trial for inoperable lung cancer.
Northwest Biotherapeutics              	DCVax-L, DCVax-Direct, DCVax Prostate       	Phase 3 trial for glioblastoma multiforme
Panacela Labs, Inc.                    	CBLI                                        	MOBILAN Adenovirus-based treatment inducing immune response. Final stage of preclinical development.
Prima BioMed LTD                       	Cvac                                        	Ovarian cancer in phase III.
Regeneus Ltd                           	RGSH4K                                      	An autologous cancer immunotherapy which uses the tumor as source material for the vaccine - in phase I
Scancell Holdings,                     	SCIB1                                       	
OncoPep, Inc                           	NCT01758328, PVX-410 (Multi-peptide vaccine)	in a phase I/II trial to treat smoldering multiple myeloma.
-- Jytdog (talk) 20:56, 6 November 2017 (UTC)
thread_title:  pipleine-ish section 

message: I suggest merging Tumor antigen vaccine into Cancer vaccine as I understand they seem identical to me. A455bcd9 (talk) 09:36, 10 January 2022 (UTC)
replies: text: Klbrain (talk) 08:08, 14 August 2022 (UTC)
thread_title:  Merger proposal 

message: Article Research Ukayclare001 (talk) 21:41, 16 November 2023 (UTC)
thread_title:  The moleculer  basis of cancer in young adults